hnRNPA2B1 has been proposed as a therapeutic target for anticancer therapy, but there are no previous reports of naturally occurring agents that can switch on targeting splicing to switch off B1 in colon cancer. Here, HNRNPA2B1 is linked to malignant colon neoplasm.